Pricing Log in Create free account

Design Therapeutics, Inc. (DSGN) vs Pharming Group N.V. Sponsored ADR (PHAR)

Design Therapeutics, Inc. and Pharming Group N.V. Sponsored ADR are both Biotechnology companies. Design Therapeutics, Inc. and Pharming Group N.V. Sponsored ADR are of similar size ($681.6M and $655.9M). Design Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Pharming Group N.V. Sponsored ADR trades at 62.4×. Pharming Group N.V. Sponsored ADR has the higher net margin (2.55% vs 0.00%) and the higher return on invested capital (5.50% vs 0.00%). Across the 17 metrics below, Pharming Group N.V. Sponsored ADR leads on 14 and Design Therapeutics, Inc. on 3.

Valuation

Metric DSGN PHAR Biotechnology median
P/E n/m 62.40 8.50
P/S 2,851.44 1.36 9.71
P/B 3.19 1.85 2.13
Price to free cash flow n/m 14.53 20.82
EV/EBITDA n/m 14.36 0.64
EV/Sales 1,933.76 1.20 9.21
Earnings yield (11.45%) 1.60% (33.15%)
Free cash flow yield (8.57%) 6.88% (25.50%)

Profitability

Metric DSGN PHAR Biotechnology median
Gross margin 0.00% 86.54% 65.16%
Operating margin 0.00% 5.04% 0.00%
Net margin 0.00% 2.55% 0.00%
Free cash flow margin 0.00% 9.38% 0.00%
Return on equity (34.13%) 3.67% (56.36%)
Return on assets (32.33%) 2.05% (48.04%)
Return on invested capital 0.00% 5.50% 0.00%

Growth

Metric DSGN PHAR Biotechnology median
Revenue growth (TTM) — 7.85% 6.02%
EPS growth (last fiscal year) (38.64%) 125.00% 30.26%
Revenue growth, 5-year CAGR — 12.13% 9.41%
Net income growth, 5-year CAGR 0.00% (40.35%) 0.00%

Health

Metric DSGN PHAR Biotechnology median
Debt to equity 0.00 0.36 0.00
Current ratio 18.86 3.01 4.72
Net debt to EBITDA 2.68 (2.21) 0.96

Dividend

Metric DSGN PHAR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DSGN PHAR Biotechnology median
Market cap 655.86m 681.61m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack